Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. SEC filings (Ticker: SCNI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scinai Immunotherapeutics Ltd. filings document foreign private issuer reporting for a Nasdaq-listed ADS issuer operating biopharmaceutical R&D and CDMO businesses. Form 6-K reports furnish current information on material agreements, clinical and regulatory disclosures for PC111 and related immunology programs, Nasdaq minimum bid price notices, capital-structure matters, and incorporation of current reports into Form F-3 and Form S-8 registration statements.
The filing record also documents the completed acquisition of Recipharm Israel Ltd., renamed Scinai Biopharma Services Ltd., including audited subsidiary financial statements and unaudited pro forma consolidated and combined financial information. Proxy and governance filings cover annual general meeting materials, ADS voting procedures, board composition changes, auditor selection, risk factors, and shareholder voting matters.
Scinai Immunotherapeutics Ltd. reports that a Euro 12 million non-dilutive grant application to fund further development of PC111, a monoclonal antibody licensed from Italian biotech Pincell srl, was not selected for funding by Poland’s National Center for Research and Development under the FENG program. PC111 is being developed for pemphigus vulgaris, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
The notification is an interim decision, and Scinai plans to appeal within the allowed 14-day period. The appeal is expected to be reviewed within about one month after submission, with a final determination anticipated before the end of 2025. The company believes aspects of the project were misconstrued or misanalyzed and will focus its appeal on those points, while cautioning there is no assurance the grant will ultimately be awarded.
Scinai Immunotherapeutics Ltd. reports that a Euro 12 million non-dilutive grant application to fund further development of PC111, a monoclonal antibody licensed from Italian biotech Pincell srl, was not selected for funding by Poland’s National Center for Research and Development under the FENG program. PC111 is being developed for pemphigus vulgaris, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
The notification is an interim decision, and Scinai plans to appeal within the allowed 14-day period. The appeal is expected to be reviewed within about one month after submission, with a final determination anticipated before the end of 2025. The company believes aspects of the project were misconstrued or misanalyzed and will focus its appeal on those points, while cautioning there is no assurance the grant will ultimately be awarded.
Scinai Immunotherapeutics Ltd. entered a new Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville), giving Scinai the right, but not the obligation, to sell up to $15.0 million of its American Depositary Shares over 36 months. The ADSs, each representing 4,000 ordinary shares, will be priced at 97% of the lowest of three daily VWAPs during the three trading days starting on the date Scinai delivers an Advance Notice, and Scinai may set a minimum price per ADS in each Advance. Yorkville’s beneficial ownership is capped at 9.99% of the company’s voting power or ordinary shares. Scinai will pay a $108,000 commitment fee, half via issuance of 35,461 ADSs and half in cash, and the prior March 3, 2025 standby equity agreement with Yorkville will terminate once the new related registration statement is declared effective.
Scinai Immunotherapeutics Ltd. submitted a Form 6-K providing a business update for the first half of 2025. The filing includes a press release, condensed interim unaudited financial statements, and an operating and financial review and prospects, each as of June 30, 2025.
The company also states that this Form 6-K, including these exhibits, is incorporated by reference into its existing registration statements on Form S-8 and Form F-3. This links the new interim information directly into Scinai’s previously filed securities registration documents.